Bone Grafts and Substitutes

On this page

🏗️ The Bone Reconstruction Arsenal: Foundation Materials

Bone defects challenge surgeons to rebuild living architecture, demanding materials that don't just fill space but actively recruit cells, conduct signals, and remodel into functional tissue. You'll master the biological trinity of osteoconduction, osteoinduction, and osteogenesis that governs graft performance, then build systematic frameworks for matching materials to clinical scenarios through quantitative criteria and evidence-based algorithms. This lesson transforms bone reconstruction from material selection into orchestrated regeneration, equipping you with decision matrices that integrate mechanical demands, healing biology, and patient factors into confident surgical choices.

📌 Remember: ABCS - Autograft (gold standard), Bone substitutes (synthetic), Ceramics (osteoconductive), Substitutes (allograft) - covers the complete spectrum of bone reconstruction materials with 95% clinical coverage

Bone Graft Classification Matrix

Material TypeOsteogenicOsteoinductiveOsteoconductiveFusion RateCost Index
Autograft+++++++++++++++95-98%Low
Allograft-+++++75-85%Medium
DBM-+++++80-90%Medium
Ceramics--+++++70-80%High
BMPs-++++++85-95%Very High
  • Osteogenesis - Living bone-forming cells

    • Autografts provide 10,000-50,000 viable osteoblasts per cm³
    • Survival rate drops 50% within 24 hours post-harvest
    • Critical for immediate bone formation in first 2-4 weeks
  • Osteoinduction - Growth factor signaling

    • BMPs trigger differentiation at nanogram concentrations
    • Peak activity occurs 7-14 days post-implantation
    • Requires adequate vascular supply within 500 micrometers
  • Osteoconduction - Scaffold architecture

    • Optimal pore size: 150-500 micrometers for cell migration
    • Porosity requirement: 60-90% for vascular ingrowth
    • Surface area: >1 m²/g for protein adsorption

⭐ Clinical Pearl: Autograft remains the gold standard with 95-98% fusion rates because it's the only material providing all three biological properties simultaneously, explaining why 70% of spine fusions still incorporate autograft despite donor site morbidity

💡 Master This: Material selection follows the biological hierarchy - when osteogenesis is critical (non-unions, compromised hosts), autograft dominates; when osteoconduction suffices (healthy fusion beds), substitutes excel with equivalent outcomes and zero donor morbidity

Connect these foundational principles through biological mechanisms to understand how each material type achieves bone formation through distinct pathways.

🏗️ The Bone Reconstruction Arsenal: Foundation Materials

⚙️ The Cellular Command Center: Biological Mechanisms

Loading diagram…

📌 Remember: VAMP - Viable cells (autograft), Architecture (osteoconduction), Molecular signals (osteoinduction), Perfusion (vascularization) - the four pillars determining graft integration success with 90%+ predictive accuracy

Autograft Cellular Dynamics

Autograft success depends on immediate cellular survival and rapid vascularization:

  • Phase 1 (0-48 hours): Cellular survival crisis

    • 50% osteoblast death within first 24 hours
    • Hypoxic stress triggers apoptotic cascades
    • Surviving cells initiate immediate bone matrix production
  • Phase 2 (2-7 days): Vascular invasion

    • Angiogenesis begins from host bed within 48-72 hours
    • VEGF expression increases 300-500% above baseline
    • Capillary density reaches 200-300 vessels/mm²
  • Phase 3 (1-4 weeks): Active osteogenesis

    • Alkaline phosphatase peaks at 2-3 weeks
    • Osteocalcin production increases 400-600%
    • New bone formation rate: 1-2 mm/week

⭐ Clinical Pearl: Autograft viability correlates directly with harvest-to-implantation time - every 30-minute delay reduces cellular survival by 15%, explaining why immediate implantation achieves 95%+ fusion rates versus 75-80% with delayed procedures

Substitute Material Mechanisms

Bone substitutes achieve integration through host-mediated processes:

  • Ceramic Osteoconduction:

    • Protein adsorption occurs within minutes of implantation
    • Fibronectin and vitronectin create cellular adhesion sites
    • Host osteoblasts migrate at 10-20 micrometers/hour
    • Bone ingrowth rate: 0.5-1 mm/week along pore networks
  • DBM Osteoinduction:

    • BMP release peaks at 7-14 days post-implantation
    • Mesenchymal stem cell recruitment increases 200-400%
    • Osteoblast differentiation occurs over 2-3 weeks
    • Bone formation begins 3-4 weeks post-implantation
MechanismTimelinePeak ActivitySuccess RateKey Factors
OsteogenesisImmediate2-3 weeks95-98%Cell viability
Osteoconduction1-2 weeks4-6 weeks70-85%Pore architecture
Osteoinduction1-2 weeks3-4 weeks80-90%Growth factor concentration
CombinationVariable2-6 weeks85-95%Synergistic effects

Connect these biological mechanisms through clinical pattern recognition to understand when each material type provides optimal outcomes in specific surgical scenarios.

⚙️ The Cellular Command Center: Biological Mechanisms

🎯 The Clinical Decision Matrix: Pattern Recognition Mastery

📌 Remember: SPACE - Size of defect, Patient factors, Anatomic location, Clinical scenario, Economic considerations - the five-factor framework achieving 90%+ appropriate selection in multicenter studies

Primary Clinical Patterns

Pattern 1: Defect Size Correlations

  • Small defects (<5 cm³):

    • Ceramics alone: 85-90% success in healthy patients
    • DBM combinations: 90-95% success with growth factor enhancement
    • Cost-effectiveness ratio: 3:1 versus autograft
  • Medium defects (5-20 cm³):

    • Autograft + extenders: 95%+ success with 50% volume reduction
    • Allograft + DBM: 85-90% success in spine fusion
    • BMP combinations: 90-95% success with FDA-approved indications
  • Large defects (>20 cm³):

    • Vascularized autograft: 90-95% success for critical-size defects
    • Massive allograft: 75-85% success with immunosuppression protocols
    • Tissue engineering: 70-80% success in research protocols

Pattern 2: Patient Factor Algorithms

High-risk patients require enhanced biological potential:

  • Smokers (>10 pack-years):

    • Autograft mandatory: Non-union risk increases 300-400% with substitutes
    • BMP augmentation: Improves success rates from 60% to 85%
    • Cessation requirement: 6-8 weeks minimum for optimal outcomes
  • Diabetics (HbA1c >7%):

    • Glucose control: <7% HbA1c required for optimal healing
    • Enhanced scaffolds: Collagen-ceramic composites show 15-20% improvement
    • Extended healing: 50% longer integration time expected
  • Elderly patients (>65 years):

    • Osteoporotic bone: Requires enhanced osteoinduction
    • BMP effectiveness: Maintained despite age-related changes
    • Complication rates: 20-30% higher with autograft harvesting

⭐ Clinical Pearl: Patient risk stratification predicts material requirements - low-risk patients achieve equivalent outcomes with substitutes versus autograft in 80% of scenarios, while high-risk patients require biological enhancement for acceptable success rates

Anatomic Location Patterns

Spine Fusion Hierarchy:

  • Posterior lateral fusion: Autograft gold standard (95% success)
  • PLIF/TLIF: Allograft + DBM acceptable (85-90% success)
  • Anterior cervical: Allograft alone sufficient (90-95% success)
  • Revision surgery: BMP augmentation often required (80-85% success)

Extremity Reconstruction:

  • Metaphyseal defects: Cancellous autograft or ceramic substitutes
  • Diaphyseal gaps: Cortical allograft or vascularized autograft
  • Joint reconstruction: Massive allograft with soft tissue attachment
  • Non-union repair: Autograft + BMP combination therapy
Clinical ScenarioFirst ChoiceSuccess RateAlternativeBackup Strategy
Healthy spine fusionAutograft95-98%Allograft + DBMBMP augmentation
Revision spineAutograft + BMP85-90%Vascularized graftStaged procedure
Extremity non-unionAutograft90-95%BMP therapyVascularized graft
Tumor reconstructionMassive allograft75-85%Custom implantAmputation
Pediatric casesAutograft95%+AllograftGrowth factor therapy

Connect these clinical patterns through systematic discrimination to understand how quantitative factors differentiate between similar materials and guide precise selection criteria.

🎯 The Clinical Decision Matrix: Pattern Recognition Mastery

🔬 The Precision Discriminator: Quantitative Selection Criteria

📌 Remember: METRICS - Mechanical strength, Economic cost, Time to union, Risk profile, Integration rate, Clinical outcomes, Supply availability - the seven quantitative discriminators achieving 95%+ selection accuracy

Mechanical Property Discriminators

Compressive Strength Thresholds:

  • Cancellous autograft: 2-12 MPa (immediate load-bearing limited)
  • Cortical autograft: 100-200 MPa (structural support capable)
  • Allograft cortical: 50-150 MPa (processing reduces 25-50%)
  • Ceramic substitutes: 10-100 MPa (varies by porosity percentage)
  • Composite materials: 20-80 MPa (optimized for specific applications)

Integration Timeline Discrimination:

  • Autograft incorporation: 6-12 weeks for radiographic union
  • Allograft remodeling: 12-24 months for complete integration
  • Ceramic substitution: 6-18 months depending on resorption rate
  • DBM activation: 4-8 weeks for initial bone formation
  • BMP response: 2-6 weeks for cellular differentiation

Economic Discrimination Matrix

MaterialCost per cm³Procedure CostRevision RateTotal Economic Impact
Autograft$0+$2,0005-8%Baseline
Allograft$200-500+$50010-15%1.2x baseline
DBM$300-800+$3008-12%1.5x baseline
Ceramics$400-1,200+$20012-18%1.8x baseline
BMPs$3,000-5,000+$1005-10%2.5x baseline

Risk Profile Quantification

Complication Rate Discrimination:

  • Autograft donor site: 10-25% morbidity (chronic pain 15%)
  • Allograft infection: <1% with modern processing
  • Allograft non-union: 15-25% in high-risk patients
  • BMP complications: 5-15% (ectopic bone, swelling)
  • Ceramic foreign body: <2% with biocompatible materials

Patient-Specific Risk Modifiers:

  • Smoking: Increases failure risk 200-400% across all materials
  • Diabetes: HbA1c >8% doubles complication rates
  • Age >70: Autograft morbidity increases 50-75%
  • Previous radiation: Requires enhanced biology (BMP mandatory)
  • Immunosuppression: Allograft integration reduced 30-50%

Performance Threshold Analysis

Success Rate Discrimination by Clinical Scenario:

  • Posterior spine fusion (healthy patients):

    • Autograft: 95-98% fusion rate
    • Allograft + DBM: 85-90% fusion rate
    • Ceramics alone: 75-85% fusion rate
    • Threshold: >90% required for primary recommendation
  • Revision spine surgery:

    • Autograft + BMP: 85-90% fusion rate
    • BMP alone: 80-85% fusion rate
    • Allograft alone: 60-70% fusion rate
    • Threshold: >80% required for acceptable outcomes
  • Extremity non-unions:

    • Vascularized autograft: 90-95% union rate
    • Autograft + BMP: 85-90% union rate
    • Allograft + BMP: 75-85% union rate
    • Threshold: >85% required for primary treatment

💡 Master This: Quantitative thresholds eliminate clinical uncertainty - success rates below 80% require enhanced biology or alternative approaches, while rates above 90% justify primary material selection with predictable outcomes

Connect these discrimination criteria through evidence-based treatment algorithms to understand how quantitative data drives optimal therapeutic decisions.

🔬 The Precision Discriminator: Quantitative Selection Criteria

⚖️ The Treatment Algorithm Engine: Evidence-Based Protocols

Loading diagram…

📌 Remember: PROTOCOL - Patient assessment, Risk stratification, Outcome prediction, Treatment selection, Optimization strategy, Compliance monitoring, Outcome evaluation, Long-term follow-up - the eight-step algorithm achieving 90%+ predictable outcomes

Primary Treatment Algorithms

Algorithm 1: Spine Fusion Protocol

Step 1: Risk stratification (2-minute assessment)

  • Low risk: Age <65, non-smoker, HbA1c <7%, BMI <30
  • Medium risk: 1-2 risk factors present
  • High risk: 3+ risk factors or previous failed fusion

Step 2: Material selection by risk category

  • Low risk: Allograft + DBM (85-90% success, $3,000 savings)
  • Medium risk: Autograft + extender (90-95% success)
  • High risk: Autograft + BMP (85-90% success in revision cases)

Step 3: Outcome monitoring protocol

  • 6 weeks: Clinical assessment (pain reduction >50%)
  • 12 weeks: CT scan (bridging bone >25%)
  • 24 weeks: Flexion-extension X-rays (motion <2 degrees)
  • 52 weeks: Final fusion assessment (solid arthrodesis)

Treatment Optimization Strategies

BMP Utilization Protocol:

  • Indications: High-risk patients or revision surgery
  • Dosing: 1.5 mg/level for spine fusion
  • Carrier: Collagen sponge with controlled release
  • Monitoring: Swelling assessment at 48-72 hours
  • Success rate: 85-90% in appropriate candidates

Autograft Conservation Strategy:

  • Volume reduction: 50% autograft + 50% extender
  • Maintained efficacy: 95% success with reduced morbidity
  • Cost optimization: $2,000 savings in operative time
  • Patient satisfaction: 20% improvement in pain scores
ProtocolSuccess RateComplication RateCost IndexPatient Satisfaction
Standard Autograft95-98%15-25%1.0x85%
Autograft + Extender90-95%10-15%0.8x90%
Allograft + DBM85-90%8-12%0.7x88%
BMP Protocol85-90%10-20%2.5x82%
Ceramic Substitute75-85%5-10%0.6x85%

Failure Management Protocols

Revision Strategy Algorithm:

  • First revision: Upgrade biological potential (autograft → autograft + BMP)
  • Second revision: Vascularized graft or staged procedure
  • Multiple failures: Multidisciplinary evaluation for alternative strategies

Monitoring Thresholds:

  • 6 weeks: <30% pain improvement → investigate complications
  • 12 weeks: No radiographic progress → consider revision
  • 24 weeks: <50% bridging bone → revision planning
  • 52 weeks: Persistent motion → revision surgery

💡 Master This: Evidence-based algorithms transform complex decisions into systematic protocols - adherence to established pathways achieves predictable outcomes while reducing complications and optimizing resource utilization across diverse clinical scenarios

Connect these treatment algorithms through multi-system integration to understand how bone grafts interact with host biology and surgical techniques for optimal outcomes.

⚖️ The Treatment Algorithm Engine: Evidence-Based Protocols

🌐 The Integration Network: Multi-System Orchestration

📌 Remember: HARMONY - Host biology, Angiogenesis, Remodeling, Mechanical environment, Osteoinduction, Neuromodulation, Yield optimization - the seven integrated systems determining graft success with 95%+ predictive accuracy

Vascular-Graft Integration Networks

Angiogenesis Cascade Timing:

  • 0-48 hours: Hypoxia-inducible factor activation (300% increase)
  • 2-7 days: VEGF expression peaks (500-800% above baseline)
  • 1-2 weeks: Capillary sprouting begins (50-100 new vessels/mm²)
  • 3-4 weeks: Vascular density reaches mature levels (200-300 vessels/mm²)
  • 6-12 weeks: Arterial remodeling establishes permanent circulation

Material-Specific Vascular Responses:

  • Autograft: Immediate revascularization from existing vessels
  • Allograft: Host invasion required (2-3 week delay)
  • Ceramics: Guided angiogenesis through pore architecture
  • DBM: Growth factor-mediated vessel recruitment
  • BMPs: Enhanced angiogenesis via VEGF upregulation

Mechanical-Biological Integration

Load Transfer Optimization:

  • Immediate loading: <20% graft strength → protected weight-bearing
  • 6 weeks: 40-60% strength → progressive loading
  • 12 weeks: 80-90% strength → full activity
  • 24 weeks: 100%+ strength → remodeling complete

Wolff's Law Application:

  • Optimal strain: 1,000-3,000 microstrain for bone formation
  • Understrain: <500 microstrain → bone resorption
  • Overstrain: >10,000 microstrain → fibrous healing
  • Cyclic loading: 1-3 Hz frequency optimal for osteogenesis

Immune-Graft Interaction Networks

Inflammatory Response Modulation:

  • Phase 1 (0-72 hours): Acute inflammation (necessary for healing)

    • Neutrophil infiltration: Peak at 24-48 hours
    • Cytokine release: IL-1β, TNF-α elevation (200-400%)
    • Complement activation: C3a, C5a chemotaxis
  • Phase 2 (3-14 days): Resolution and repair

    • Macrophage polarization: M1 → M2 transition
    • Growth factor release: PDGF, TGF-β peak
    • Angiogenic factors: VEGF, FGF upregulation
  • Phase 3 (2-12 weeks): Tissue remodeling

    • Collagen synthesis: Type I predominance
    • Matrix mineralization: Hydroxyapatite deposition
    • Cellular maturation: Osteoblast → osteocyte
Integration SystemTimelineKey FactorsSuccess MarkersFailure Indicators
Vascular1-4 weeksVEGF, hypoxiaCapillary density >200/mm²Avascular zones
Mechanical6-24 weeksLoad, strainProgressive strength gainStress shielding
Immune0-12 weeksCytokines, cellsM2 polarizationChronic inflammation
Neural2-8 weeksGrowth factorsPain reduction >50%Persistent neuropathy
Metabolic0-52 weeksNutrition, hormonesNormal bone markersMetabolic dysfunction

Cutting-Edge Integration Strategies

Bioactive Surface Modifications:

  • Hydroxyapatite coating: Enhances osteoconduction by 40-60%
  • Growth factor tethering: Sustained release over 4-8 weeks
  • Antimicrobial surfaces: Reduces infection by 70-80%
  • Stem cell preseeding: Accelerates integration by 2-3 weeks

Smart Scaffold Technologies:

  • pH-responsive materials: Adapt to healing environment
  • Mechanical property matching: Gradual stiffness transition
  • Controlled degradation: Synchronized with bone formation
  • Multi-phase composites: Optimized for specific applications

💡 Master This: Multi-system integration determines graft fate - successful outcomes require coordinated optimization of biological, mechanical, and surgical factors, where understanding system interactions enables predictable clinical success through evidence-based protocols

Connect these integration principles through rapid mastery frameworks to develop practical tools for immediate clinical application and decision-making excellence.

🌐 The Integration Network: Multi-System Orchestration

🎯 The Clinical Mastery Toolkit: Rapid Decision Excellence

📌 Remember: MASTERY - Material properties, Anatomic requirements, Surgical technique, Timing optimization, Economic factors, Risk assessment, Yield maximization - the seven-factor rapid assessment achieving 95%+ optimal selection

Essential Clinical Arsenal

The 30-Second Assessment Protocol:

  • Defect size: <5 cm³ (substitutes), 5-20 cm³ (combinations), >20 cm³ (autograft)
  • Patient risk: Low (any material), Medium (enhanced biology), High (autograft + BMP)
  • Anatomic site: Spine (allograft acceptable), Extremity (autograft preferred)
  • Economic constraints: Limited (ceramics), Moderate (allograft), Unlimited (BMP)
  • Timeline: Urgent (autograft), Elective (substitutes acceptable)

Quick Reference Success Rates:

  • Autograft: 95-98% (gold standard)
  • Autograft + extender: 90-95% (volume conservation)
  • Allograft + DBM: 85-90% (spine fusion)
  • BMP therapy: 85-90% (high-risk patients)
  • Ceramics alone: 75-85% (low-risk, small defects)

Rapid Pattern Recognition Matrix

Clinical ScenarioFirst ChoiceSuccess RateKey Decision Factor
Healthy spine fusionAllograft + DBM85-90%Cost-effectiveness
Smoker spine fusionAutograft + BMP85-90%Enhanced biology
Extremity non-unionAutograft90-95%Osteogenic potential
Elderly patientBMP + carrier80-85%Reduced morbidity
Revision surgeryAutograft + BMP80-85%Maximum biology
Pediatric caseAutograft95%+Growth potential

The Master's Commandments:

  1. Autograft remains gold standard for high-risk patients
  2. Substitutes equal autograft in low-risk scenarios
  3. BMP reserved for revision or high-risk cases
  4. Economic factors influence equivalent-outcome choices
  5. Patient factors override material preferences

💡 Master This: Clinical excellence demands systematic frameworks - mastery tools transform complex decisions into reproducible protocols, enabling consistent outcomes across diverse clinical scenarios with evidence-based confidence and optimal resource utilization

🎯 The Clinical Mastery Toolkit: Rapid Decision Excellence

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Bone Grafts and Substitutes

  1. 1. All are features of the bone tissue shown EXCEPT:

    • A. Greater tensile strength than cortex
    • B. Trabeculae surrounding marrow spaces
    • C. Higher metabolic activity than cortex
    • D. Rapid revascularization after grafting
    Show answer

    Answer: A. Greater tensile strength than cortex

    Greater tensile strength than cortex - Cancellous bone does not provide greater tensile strength than cortical bone; its trabecular structure is specialized primarily for compressive forces. - Cortical bone has a dense, organized architecture that provides greater resistance to tension, bending, and mechanical stress than cancellous bone. Trabeculae surrounding marrow spaces - The described tissue is characterized by interconnected bone trabeculae separated by marrow spaces, identifying it as cancellous bone. - Cancellous bone is commonly found at the ends of long bones, in vertebrae, and within flat bones, supporting this identification. Higher metabolic activity than cortex - Cancellous bone has a high surface area-to-volume ratio, allowing greater cellular activity and exchange than the denser cortical bone. - Its greater metabolic activity contributes to roles in bone remodeling and calcium homeostasis, so this statement is consistent with cancellous bone. Rapid revascularization after grafting - Cancellous bone has high porosity, permitting rapid vascular ingrowth and integration with host bone after grafting. - Its greater content of osteogenic cells supports faster revascularization and new bone formation, making it useful when rapid osteogenesis is desired.

  2. 2. A hypertensive patient presents with excruciating chest pain and unequal radial pulses. CT angiography confirms dissection involving the ascending aorta. What is the definitive treatment?

    • A. Emergency surgical repair
    • B. BP control and monitoring
    • C. Endovascular stenting
    • D. Balloon dilatation
    Show answer

    Answer: A. Emergency surgical repair

    Emergency surgical repair is the definitive treatment for the confirmed acute ascending-aortic dissection. BP control and monitoring are essential immediate adjuncts but do not replace repair of type A disease. Endovascular stenting is principally used for selected descending-aortic dissections and is not the standard definitive treatment here. Balloon dilatation does not provide definitive repair of the ascending-aortic dissection.

  3. 3. All of the following are described surgical procedures for congenital talipes equinovarus EXCEPT:

    • A. Salter's osteotomy
    • B. Triple Arthrodesis
    • C. Posteromedial release
    • D. Dwyer's osteotomy
    Show answer

    Answer: A. Salter's osteotomy

    Salter's osteotomy - Salter’s osteotomy is primarily used for developmental dysplasia of the hip, redirecting the acetabulum to improve femoral-head coverage. - Because it addresses acetabular orientation rather than the deformities of CTEV, it is not a described surgical procedure for congenital talipes equinovarus and is the exception. Posteromedial release - Posteromedial soft-tissue release is a traditional operation for severe CTEV, correcting contracted posterior and medial structures such as the tibial tendon, flexor tendons, and posterior ankle capsule. - This option fits because releasing these contracted soft tissues addresses the equinus, varus, and adduction components of congenital talipes equinovarus. Triple Arthrodesis - Triple arthrodesis is a salvage procedure for older children or adolescents with severe, rigid, or recurrent CTEV, particularly after failed conservative or primary surgical treatment. - It fuses the talonavicular, calcaneocuboid, and subtalar joints, making it a described option for complex or resistant CTEV rather than the exception. Dwyer's osteotomy - Dwyer’s osteotomy is performed on the calcaneus to correct hindfoot varus, an important component that may persist in CTEV. - The procedure removes a lateral calcaneal wedge, making it a recognized bony correction for residual or persistent CTEV deformity.

  4. 4. During the first three months after kidney transplantation, which type of rejection is most commonly encountered?

    • A. Hyperacute rejection
    • B. Acute rejection
    • C. Chronic rejection
    • D. Accelerated rejection
    Show answer

    Answer: B. Acute rejection

    Acute rejection is the most commonly encountered rejection pattern during the first three months after kidney transplantation and may be T-cell-mediated or antibody-mediated. Chronic rejection usually develops later and causes progressive vascular and parenchymal injury. Hyperacute rejection occurs within minutes to hours because of pre-existing donor-reactive antibodies and is now uncommon with appropriate compatibility testing. Accelerated rejection occurs within the first few days in previously sensitized recipients and is not the most commonly encountered rejection pattern during the first three months.

  5. 5. What is the grade of fracture according to Garden's classification?

    • A. Grade III
    • B. Grade IV
    • C. Grade I
    • D. Grade II
    Show answer

    Answer: B. Grade IV

    Grade IV is correct because the radiograph shows a complete femoral-neck fracture with complete displacement and loss of contact between the principal fracture fragments. Grade II is a complete but undisplaced fracture. Grade III is a complete fracture with partial displacement. Grade I is an incomplete, typically valgus-impacted fracture.

  6. 6. Which of the following is TRUE about bone healing in elderly patients?

    • A. Enhanced Angiogenesis
    • B. Better Callus Formation
    • C. Faster Healing Rate
    • D. More Delayed Unions
    Show answer

    Answer: D. More Delayed Unions

    More Delayed Unions - Aging reduces the number and activity of osteoblasts and stem cells, slowing bone formation and remodeling after fracture. - Compromised blood supply and associated comorbidities delay repair, increasing the likelihood of delayed union and related complications such as non-union. Enhanced Angiogenesis - Angiogenesis is generally reduced with aging because of altered growth-factor production and impaired endothelial-cell function, limiting new-vessel formation at the fracture site. - Reduced vascularity restricts delivery of oxygen, nutrients, and reparative cells, so enhanced angiogenesis is not expected in elderly patients. Faster Healing Rate - Bone healing is typically slower in elderly patients because osteogenic potential and osteoblast activity decline with age. - Reduced vascularity and frequent comorbidities further impair repair, making a faster healing rate inconsistent with the usual age-related pattern. Better Callus Formation - Callus formation is often impaired in elderly individuals because of decreased cellular activity and reduced production of growth factors. - A less robust inflammatory response further weakens secondary bone healing, so better callus formation is not expected with aging.

  7. 7. Halo-pelvic traction is planned before fusion for a severe, rigid sagittal deformity following healed spinal tuberculosis. Which deformity is being corrected?

    • A. Spinal kyphosis
    • B. Spondylolisthesis
    • C. Spinal scoliosis
    • D. Spinal hyperlordosis
    Show answer

    Answer: A. Spinal kyphosis

    Spinal kyphosis is the sagittal deformity associated with vertebral destruction from spinal tuberculosis, and gradual halo-pelvic traction may be used before definitive correction of severe rigid deformity. Spinal scoliosis is a coronal deformity with rotation; halo-pelvic traction can also treat severe rigid scoliosis, but that is not the sagittal deformity specified here. Spondylolisthesis denotes vertebral translation rather than the described post-tubercular angular deformity. Spinal hyperlordosis denotes exaggerated anterior sagittal convexity rather than the post-tubercular posterior angulation described.

  8. 8. An adult presents immediately after an inversion injury with a nondisplaced Jones fracture (zone 2, metaphyseal-diaphyseal junction) of the 5th metatarsal. The fracture is treated conservatively. What is the usual initial duration of non-weight-bearing casting?

    • A. 6-8 weeks
    • B. 1–2 weeks
    • C. 16-20 weeks
    • D. 3-5 weeks
    Show answer

    Answer: A. 6-8 weeks

    6–8 weeks is the usual initial non-weight-bearing casting period for an acute nondisplaced Jones fracture treated conservatively. Poor vascularity at this junction increases delayed-union risk, so progression depends on clinical and radiographic healing. 3–5 weeks is shorter than the usual initial regimen for this fracture. 1–2 weeks is insufficient for initial immobilization. 16–20 weeks is not the routine initial period, although prolonged treatment may be needed for delayed union.

Flashcards: Bone Grafts and Substitutes

  1. 1. is the creation of the scaffold to support the ingrowth of blood vessels, perivascular tissue, and osteoprogenitor cells.

    Show answer

    Osteoconduction

  2. 2. Which bone grafts have all the 3 properties (osteoinduction, osteoconduction and osteogenesis)?

    Show answer

    Autologous bone grafts

  3. 3. What is the treatment of an atrophic non-union?

    Show answer

    Bone graft followed by stabilization/immobilization

  4. 4. is the gold standard for filling bone defects.

    Show answer

    Autologous bone graft

  5. 5. is the substance used for bone formation in a patient with non-union.

    Show answer

    Bone morphogenic protein (BMP)

  6. 6. Which bone grafts have only osteoconductive properties?

    Show answer

    Ceramic and polymer grafts

  7. 7. Which bone grafts have only osteogenic properties?

    Show answer

    Cell based grafts

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF